Aernoud P. Bavinck

Aernoud P. Bavinck

Auto-generated profile, based on publicly available information

Aernoud P. Bavinck

Department of Hematology Radboud University Medical Centre Nijmegen The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in JMIR Formative Research
Verified
Journal Article
Open access
ABAernoud Bavinck
Aernoud Bavinck
SSSaskia Schols
Saskia Schols
WTWilfred Teunissen
Wilfred Teunissen
ASAmy Shapiro
Amy Shapiro
NBNicole Blijlevens
Nicole Blijlevens
WHWaander van Heerde
Waander van Heerde
Background: Hemophilia A is an inherited bleeding disorder with an increased risk of excessive bleeding. People affected by hemophilia A with a severe bleeding phenotype are treated prophylactically with hemostatic agents. Monitoring treatment and adjusting it to the individual patient’s needs is complicated by the scarcity of laboratories equipped to perform relevant coagulation assays and the absence of point-of-care testing platforms. A novel near-patient testing platform called the EnzySystem HemA aims to address this issue by measuring factor VIII (FVIII) activity and thrombin generation within 1 hour of 100 µL of whole blood. Objective: This study assessed the usability of the EnzySystem HemA by health care professionals without prior training and gathered information on its perceived usability, effectiveness, usefulness, and acceptability. Methods: A qualitative, single-center formative usability assessment was performed. Participants performed an FVIII activity assay with a mockup of the EnzySystem HemA and were interviewed about its acceptability, usability, effectiveness, and usefulness. Video recordings of the sessions were obtained with permission and subsequently reviewed to assess usability; thematic analysis was performed on the interview transcripts. Results: A total of 7 health care providers participated, all unaffiliated with the EnzySystem’s developer. Participants included 1 (14%) pediatric hematologist, 3 (43%; pediatric) nurses, and 3 (43%; pediatric) nurse practitioners. Two (29%) of the participants also held management positions. Five (71%) participants successfully performed the FVIII activity assay as intended. Of the remaining 2 participants, one applied insufficient force when inserting the blood tube, whereas the other was unable to transfer the blood into the EnzySystem. This latter step caused difficulties in 3 (60%) other participants; however, they completed it correctly. Five (71%) participants did not dispose of the EnzySystem components as intended, primarily due to compatibility issues of the disposable parts with the inlet of the US standard medical waste containers. Five themes were generated from the interviews: functional the way it is focuses on the acceptance of the prototype despite suggestions for various improvements, utility through faster results and increased access and potential for patient engagement relate to the envisioned benefits of the platform, and financial investment and return and ensuring accuracy reflect on potential barriers for implementation. Conclusions: Despite significant usability issues, the need for faster and more accessible testing led participants to conclude that the current platform was acceptable for use, provided that proof of assay accuracy was demonstrated. The results of this study will form the basis for further development of the EnzySystem HemA. The effectiveness of any updates will be evaluated in future usability studies, which will also include people with hemophilia A as participants.

17 December 2025 in Haemophilia
Verified
Journal Article
Open access
ABAernoud P. Bavinck
Aernoud P. Bavinck
KDKyle Davis
Kyle Davis
LELisa van Engelshoven
Lisa van Engelshoven
MLMonique G. van Lier
Monique G. van Lier
THTanja Hamacher
Tanja Hamacher
WHWaander L. van Heerde
Waander L. van Heerde
Introduction: Coagulation testing in haemophilia A is limited by the scarcity of testing facilities capable of performing relevant assays. This issue incentivized the development of the EnzySystem for haemophilia A, a near‐patient testing platform aimed to measure Factor VIII activity and thrombin generation simultaneously within 1 h from 100 µL of whole blood. Involving end‐users throughout the development ensures innovations are well‐suited to meet real‐world clinical needs. Aim: To determine EnzySystem's acceptance, envisioned use scenarios and determinants for implementation according to healthcare providers (HCPs) and persons with haemophilia A and caregivers (PwHA/C). Methods: A single‐centre, cross‐sectional mixed methods study was performed involving two participant groups. The first involved 36 PwHA/C. The second group comprised five advanced practice providers, eight nurses, four pharmacists and five haematologists, all involved in haemophilia A care. The participants’ attitudes and preferences toward the EnzySystem for haemophilia A were assessed through questionnaires and focus groups. Results: Acceptability was high for both groups. The platform was considered suitable for use in various scenarios, but self‐testing at home was prioritized by PwHA/C. HCPs placed equal emphasis on near‐patient testing in clinic to address issues with current test accessibility and turnaround time. For all potential use scenarios, demonstrating assay accuracy was a non‐negotiable prerequisite. The turnaround time and accessibility were identified as other key attributes by both groups. Conclusion: The results of this study support the further development of the EnzySystem for haemophilia A and highlight barriers that should be addressed to facilitate implementation.

16 May 2025 in JMIR Preprints
Verified
Preprint
Open access
ABAernoud Bavinck
Aernoud Bavinck
SSSaskia Schols
Saskia Schols
WTWilfred Teunissen
Wilfred Teunissen
ASAmy Shapiro
Amy Shapiro
NBNicole Blijlevens
Nicole Blijlevens
WHWaander van Heerde
Waander van Heerde
BACKGROUND Hemophilia A is an inherited bleeding disorder with an increased risk of excessive bleeding. People affected by hemophilia A with a severe bleeding phenotype are treated prophylactically with hemostatic agents. Monitoring treatment and adjusting it to the individual patient’s needs is complicated by the scarcity of laboratories equipped to perform relevant coagulation assays and the absence of point-of-care testing platforms. A novel near-patient testing platform called the EnzySystem HemA aims to address this issue by measuring Factor VIII activity and Thrombin Generation within one hour out of 100 µL of whole blood. OBJECTIVE This study assessed the usability of the EnzySystem HemA by healthcare professionals without prior training and gathered information on its perceived usability, effectiveness, usefulness, and acceptability. METHODS A qualitative, single-center formative usability assessment was performed. Seven healthcare providers participated, all unaffiliated with the EnzySystem’s developer (Enzyre). Participants included one pediatric hematologist, three (pediatric) nurses, and three (pediatric) nurse practitioners. Two of the participants also held management positions. Participants performed a FVIII activity assay with a mockup of the EnzySystem HemA and were interviewed about its acceptability, usability, effectiveness, and usefulness. Video recordings of the sessions were obtained with permission and subsequently reviewed to assess usability; thematic analysis was performed on the interview transcripts. RESULTS Five participants (71%, 5/7) successfully performed the FVIII activity assay as intended. Of the remaining two participants, one applied insufficient force when inserting the blood tube, while the other was unable to transfer the blood into the EnzySystem. This latter step caused difficulties in three other participants, however they completed it correctly. Five participants (71%, 5/7) did not dispose of the EnzySystem components as intended, primarily due to compatibility issues of the disposable parts with the inlet of US standard medical waste containers. Five themes were generated from the interviews: “Functional the way it is” focuses on the acceptance of the prototype despite suggestions for various improvements; “Utility through faster results and increased access” and “Potential for patient engagement” relate to the envisioned benefits of the platform; and “Financial investment and return” and “Ensuring accuracy” reflect on potential barriers for implementation. CONCLUSIONS Despite significant usability issues, the need for faster and more accessible testing led participants to conclude that the current platform was acceptable for use, provided that proof of assay accuracy was demonstrated. The results of this study will form the basis for further development of the EnzySystem HemA. The effectiveness of any updates will be evaluated in future usability studies, which will also include people with hemophilia A as participants. CLINICALTRIAL

27 August 2026 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
ABAernoud P. Bavinck
Aernoud P. Bavinck
TSTheodora J. Steeghs
Theodora J. Steeghs
LELisa van Engelshoven
Lisa van Engelshoven
NCNerissa M.M. Coolen
Nerissa M.M. Coolen
CRClaudia J. van de Ridder
Claudia J. van de Ridder
WHWaander L. van Heerde
Waander L. van Heerde